INGNQ Stock UPDATES Introgen Therapeu (INGNQ) 0.0001 09/22/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Introgen Therapeu (INGNQ) 0.0001 $INGNQ

Market Research Report: Cancer Gene Therapy Market Analysis
M2 - Thu Mar 20, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h59s3c/cancer_gene) has announced the addition of the "Cancer Gene Therapy Market Analysis" report to their offering. The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer. A major part of the cancer gene therapy products for are currently in preclinical and Phase II of clinical trials. There has been marginal success in developing completely curative therapeutic drugs. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Gendicine, which is developed by Shenzhen SiBiono Gene Technologies Co., is currently marketed only in China and Rexin-G in Philippines. Gene therapy offers a large window of opportunities for the treatment of multiple cancers. The therapy has been found to be able to deliver special tumor suppressor genes to an individual, which could prevent the growth of malignant tumors and also reduce the metastatic disease. . The major concentration is being given to the rare tumor types such as pancreatic cancer, and highly prevalent tumor types such as breast cancer and prostate cancer. With the prevalence of cancer rising significantly, the future drug pipelines of the companies are mostly focusing on gene therapy for cancer. Cancer Gene Therapy Report Highlights & Findings: - Highest Number of Drugs in Preclinical Stage: 37 - Suspended & Discontinued Cancer Gene Therapy Drug Pipeline: 100 - Significance of Oncology Therapeutics in Gene Therapy - Current Applications of Gene Therapy to Cancer Treatment - Favorable Parameters for Cancer Gene Therapy - Issued Involved with Application of Gene Therapy in Cancer Patients - Regulatory Scenario for Gene Therapy Market - Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications Companies Mentioned - Advantagene - BioCancell - Celgene - Cell Genesys - Epeius Biotechnologies - GenVec - Introgen Therapeutics - MultiVir - Shenzhen SiBiono GeneTech - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/h5...ancer_gene About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lilly's Retatrutide Outshines Ozempic in Key Diabetes Trial

Updated Category News Views 24

Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...

Continue Reading
Samuel Oschin Air & Space Center Takes Flight This Fall

Updated Category News Views 98

The Grand Unveiling: November Highlights Look at this: space nerds, dreamers, and just about anybody with a heartbeat and a sense of wonder should circle November 13, 2026, like a kid with a candy store gift card. That's when the California Science Center throws open the doors to the Samuel Oschin Air and Space Center. You might as well slap a 'world's first' sticker on...

Continue Reading
Unicycive Faces Legal Heat: Shareholder Lawsuit Looms

Updated Category News Views 104

The Unicycive Landslide: What Went Down? Investors, buckle up. Unicycive Therapeutics Inc. (NASDAQ: UNCY) finds itself deep in the muck of a securities class action. Chief honchos, CEO Shalabh Gupta and CFO John Townsend, are taking the heat for allegedly controlling company disclosures that led shareholders to believe in non-existent progress with their third-party...

Continue Reading
Navigating Gas-to-AI Power: Challenges & Opportunities

Updated Category News Views 83

Natural Gas Abundance Meets Conversion Hurdles It’s a wild scene when you've got oodles of natural gas but struggle to get it into AI data centers. That’s the picture today: U.S. gas production hitting a high of 137 billion cubic feet daily, while converting that gas into practical energy is the real challenge. You see, the gas market is ready to rumble, ticking...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Replay Sports Cards Nets STAR Award for Innovation

Updated Category News Views 82

A New Era for Franchise Onboarding Just when you think the sports card world couldn't get any more niche, along comes Replay Sports Cards thumping its chest with some serious innovation. This Charlotte-based franchise just snagged the Franchise Innovation Award from Franchise Update Media. Yep, they're the only ones getting tips of the hat for the Most Innovative...

Continue Reading
Step into Fear: Dead by Daylight in Moreno Valley

Updated Category News Views 54

Immersive Horror in Moreno Valley Walking straight into the fog of your nightmares isn't for the faint-hearted, but that's the kind of thrill the Moreno Valley Museum & ArtSpace is serving up with its new Dead by Daylight Immersive Experience. Kicking off just in time for Halloween on October 30, this isn't your average stroll in a museum—it's a heart-pounding,...

Continue Reading
Armani/Casa Miami Earns Forbes Designation for Luxury

Updated Category News Views 34

Where Luxury Meets Thoughtfulness Residences by Armani/Casa Miami just nabbed a VERIFIED™ Luxury Residences badge from the Forbes Travel Guide folks. Now, you might be wondering why this is significant or if it's just another shiny tag in a world already glistening with luxury concepts. Well, there's a shift happening here, and it's got some meat to it. The folks...

Continue Reading
South Dakota's BEES Launch: Child Care Assistance Goes Live

Updated Category News Views 24

RedMane and South Dakota DSS: A New Milestone Talk about a leap into the digital age. South Dakota's Department of Social Services, teaming up with RedMane Technology, has just rolled out the Child Care Assistance Program on their BEES platform. That’s Benefits Eligibility and Enrollment System for those not keeping track. It represents a significant step in making life...

Continue Reading
QFIN Faces Lawsuit Over Broken Promises and Revenue Plunge

Updated Category News Views 48

Unmasking the Hype: QFIN's Pledge and Performance Investors, gather 'round because QFIN's latest uproar ain't pretty. The folks over at Qfin Holdings have found themselves in hot water, facing a class action lawsuit for allegedly pulling the wool over investors' eyes. Between March and August 2026, they promised a rock-solid ship braving China’s regulatory storm. Turns...

Continue Reading

Top 5 Most Recently Viewed Articles

BCMGlobal Takes Charge of NFSC's Loan Servicing Evolution

Updated Category News Views 197

BCMGlobal's New Role in Advancing NFSC BCMGlobal has been appointed to strategically manage the National Financing Support Services Company (NFSC), elevating it to a leading independent loan servicer. This initiative aims to promote excellence in the sector. Supporting Saudi Arabia's Financial Vision The NFSC, established with the backing of the Saudi Real Estate...

Continue Reading
Breakthrough MRD Data from Myriad Genetics at Cancer Conference

Updated Category News Views 201

Innovative Insights into MRD Testing Myriad Genetics, Inc. (NASDAQ: MYGN), a prominent name in molecular diagnostics and precision medicine, is set to unveil exciting new clinical findings related to their Precise MRD test at a significant annual meeting dedicated to cancer research. Presentation Highlights During the conference, Dr. Chad Tang from The University of Texas...

Continue Reading
SBM Offshore's Recent Share Buyback Program: Key Insights

Updated Category News Views 119

SBM Offshore's Share Buyback Program Overview SBM Offshore has recently reported on its significant share repurchase program, valued at EUR130 million (approximately US$140 million), covering transactions made from November 21, 2024, to November 27, 2024. This initiative underscores the company’s commitment to enhancing shareholder value through systematic buybacks. Key...

Continue Reading
Investigation into Akero Therapeutics by Berger Montague PC

Updated Category News Views 165

Akero Therapeutics Under Investigation by Berger Montague Berger Montague PC, a respected law firm, recently brought to attention an ongoing investigation into the practices of Akero Therapeutics, Inc. The investigation focuses on potential breaches of fiduciary duties and violations of federal securities laws by Akero’s Board of Directors, which has crucial...

Continue Reading
Nkarta's Upcoming Interactive Session: What to Expect?

Updated Category News Views 127

Nkarta to Engage with Investors in H.C. Wainwright Series Nkarta, Inc. (NASDAQ: NKTX), a pioneering clinical-stage biopharmaceutical firm dedicated to creating innovative engineered natural killer (NK) cell therapies, recently announced its notable role in the H.C. Wainwright "HCW@Home" Series. This virtual series will allow investors and interested parties to gain deeper...

Continue Reading